Constructing shared genetic architecture between bioavailable testosterone and luminal A breast cancer in female.

Breast Cancer

Department of General Surgery, The First Affiliated Hospital of Anhui Medical University, 218 Jixi Road, Shushan District, Hefei, 230022, Anhui, People's Republic of China.

Published: July 2025


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Background: Observational studies have showed a strong association between bioavailable testosterone (BT) and breast cancer. However, the role of genetic factors in their comorbidity remains unknown.

Methods: Using large genome-wide association study (GWAS) data, we employed linkage disequilibrium score regression (LDSC) to identify the breast cancer subtype most genetically correlated with BT. We then constructed the shared genetic architecture between BT and this subtype by: (1) applied Heritability Estimation from Summary Statistics for local genetic correlations and stratified-LDSC for partitioned heritability; (2) performed a cross-trait GWAS meta-analysis to find novel single-nucleotide polymorphism (SNP) and validated through colocalization; (3) conducted both cross-tissue and single-tissue transcriptome-wide association studies (TWAS) and validated the candidate genes through Mendelian randomization (MR); (4) investigated SNP-heritability enrichment at the gene set, tissue, and cell levels using Multi-marker Analysis of GenoMic Annotation.

Results: Luminal A breast cancer (Luminal ABC) was selected as it is a common subtype of breast cancer and demonstrates a superior genetic correlation with BT. We identified strong local correlations in 132 distinct genomic regions and confirmed shared SNPs including rs1432679 and rs7175852. TWAS highlighted two pleiotropic genes, MICALL1 and TRIOBP, with TRIOBP validated by MR. We also found six shared pathways and luminal cells in mammary gland pregnancy shared between BT and Luminal ABC. For tissue-specific enrichment, BT was mainly found in the liver and adrenal gland, whereas Luminal ABC was found in the minor salivary gland.

Conclusions: This study sheds light on the genetic architecture of BT and Luminal ABC and suggests new avenues for research and therapy.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12282-025-01696-5DOI Listing

Publication Analysis

Top Keywords

breast cancer
20
luminal abc
16
genetic architecture
12
shared genetic
8
bioavailable testosterone
8
luminal breast
8
luminal
7
genetic
6
breast
5
cancer
5

Similar Publications

Introduction: Cutaneous scalp metastases from breast carcinoma (CMBC) represent an uncommon manifestation of metastatic disease, with heterogeneous clinical presentations, including nodular or infiltrative lesions and scarring alopecia (alopecia neoplastica). The absence of standardized diagnostic criteria, particularly for alopecic phenotypes, poses challenges to early recognition of CMBC, which may represent either the first indication of neoplastic progression or a late recurrence.

Materials And Methods: We retrospectively analyzed a multicenter cohort of 15 patients with histologically confirmed CMBC.

View Article and Find Full Text PDF

PRMT1-Mediated PARP1 Methylation Drives Lung Metastasis and Chemoresistance via P65 Activation in Triple-Negative Breast Cancer.

Research (Wash D C)

September 2025

State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.

Triple-negative breast cancer (TNBC) is the most aggressive breast cancer subtype, characterized by a high propensity for metastasis, poor prognosis, and limited treatment options. Research has demonstrated a substantial correlation between the expression of protein arginine N-methyltransferase 1 (PRMT1) and enhanced proliferation, metastasis, and poor outcomes in TNBC. However, the specific role of PRMT1 in lung metastasis and chemoresistance remains unclear.

View Article and Find Full Text PDF

Purpose: This study aimed to conduct functional proteomics across breast cancer subtypes with bioinformatics analyses.

Methods: Candidate proteins were identified using nanoscale liquid chromatography with tandem mass spectrometry (NanoLC-MS/MS) from core needle biopsy samples of early stage (0-III) breast cancers, followed by external validation with public domain gene-expression datasets (TCGA TARGET GTEx and TCGA BRCA).

Results: Seventeen proteins demonstrated significantly differential expression and protein-protein interaction (PPI) found the strong networks including COL2A1, COL11A1, COL6A1, COL6A2, THBS1 and LUM.

View Article and Find Full Text PDF

A strategy for targeting tumor-associated hypoxia utilizes reductase enzyme-mediated cleavage to convert biologically inert prodrugs to their corresponding biologically active parent therapeutic agents selectively in areas of pronounced hypoxia. Small-molecule inhibitors of tubulin polymerization represent unique therapeutic agents for this approach, with the most promising functioning as both antiproliferative agents (cytotoxins) and as vascular disrupting agents (VDAs). VDAs selectively and effectively disrupt tumor-associated microvessels, which are typically fragile and chaotic in nature.

View Article and Find Full Text PDF

Breast cancer continues to present a major clinical hurdle, largely attributable to its aggressive metastatic behavior and the suboptimal efficacy of standard chemotherapeutic regimens. Cisplatin (CDDP) is a representative platinum drug in the treatment of breast cancer, however, its therapeutic application is often constrained by systemic toxicity and the frequent onset of chemoresistance. Here, we introduce a novel charge-adaptive nanoprodrug system, referred to as PP@, engineered to respond to tumor-specific conditions.

View Article and Find Full Text PDF